Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

Charlotte Rigaud; Samuel Abbou; Véronique Minard-Colin; Birgit Geoerger; Jean Yves Scoazec; Gilles Vassal; Nabaz Jaff; Laurence Heuberger; Dominique Valteau-Couanet; Laurence Brugieres

doi:10.1002/pbc.26902

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

Charlotte Rigaud, Samuel Abbou, Véronique Minard-Colin, Birgit Geoerger, Jean Yves Scoazec, Gilles Vassal, Nabaz Jaff, Laurence Heuberger, Dominique Valteau-Couanet, Laurence Brugieres

Research output: Contribution to journal › Letter › peer-review

45 Citations (Scopus)

Original language	English
Article number	e26902
Journal	Pediatric Blood and Cancer
Volume	65
Issue number	4
DOIs	https://doi.org/10.1002/pbc.26902
Publication status	Published - 1 Apr 2018

Access to Document

10.1002/pbc.26902

Cite this

@article{c07eb67716f3440fb8e06d9fbcaf1fd7,

title = "Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma",

author = "Charlotte Rigaud and Samuel Abbou and V{\'e}ronique Minard-Colin and Birgit Geoerger and Scoazec, {Jean Yves} and Gilles Vassal and Nabaz Jaff and Laurence Heuberger and Dominique Valteau-Couanet and Laurence Brugieres",

note = "Funding Information: S.A. and B.G. report receiving honoraria for consulting from Bristol-Myers Squibb. V.M. reports research funding from Roche and Bristol-Myers Squibb. G.V. reports being the main investigator of the AcS{\'e} crizotinib trial and Advisory consultant to Bristol Myer Squibb without personal remuneration. L.B. reports being member of an advisory board for Takeda without personal remuneration. The other authors declare no competing interests.",

year = "2018",

month = apr,

day = "1",

doi = "10.1002/pbc.26902",

language = "English",

volume = "65",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "4",

}

TY - JOUR

T1 - Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

AU - Rigaud, Charlotte

AU - Abbou, Samuel

AU - Minard-Colin, Véronique

AU - Geoerger, Birgit

AU - Scoazec, Jean Yves

AU - Vassal, Gilles

AU - Jaff, Nabaz

AU - Heuberger, Laurence

AU - Valteau-Couanet, Dominique

AU - Brugieres, Laurence

N1 - Funding Information: S.A. and B.G. report receiving honoraria for consulting from Bristol-Myers Squibb. V.M. reports research funding from Roche and Bristol-Myers Squibb. G.V. reports being the main investigator of the AcSé crizotinib trial and Advisory consultant to Bristol Myer Squibb without personal remuneration. L.B. reports being member of an advisory board for Takeda without personal remuneration. The other authors declare no competing interests.

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85036519431&partnerID=8YFLogxK

U2 - 10.1002/pbc.26902

DO - 10.1002/pbc.26902

M3 - Letter

C2 - 29193772

AN - SCOPUS:85036519431

SN - 1545-5009

VL - 65

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

M1 - e26902

ER -

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

Access to Document

Other files and links

Cite this